Switzerland· 68797001

Elzonris

A tagraxofusp product containing tagraxofuspum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01XX67

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedElzonrisATCL01XX67REGISTER NO.68797001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Tagraxofusp is registered in 10 of 19 countries.

Countries holding a registration under ATC L01XX67 (tagraxofusp), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Tagraxofusp · ATC L01XX67

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
tagraxofuspum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01XX67
ATC class
Tagraxofusp
Defined daily dose
0.2 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680687970013
    Durchstf 1 ml
    CHF 16973.65

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for tagraxofusp.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tagraxofusp · interactions on record

82 records

  • 9 severe
  • 73 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tagraxofusp in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tagraxofusp products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Elzonris
  • Liechtenstein · Elzonris
  • Norway · Elzonris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/60c626d4-fc6e-498d-bbc3-e1a7aab601b5
GET /v1/drugs/60c626d4-fc6e-498d-bbc3-e1a7aab601b5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "tagraxofuspum 1 mg",
  "valid_from": "2026-07-01",
  "limitations": "[{\"description\":\"Die Therapie mit ELZONRIS bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nELZONRIS (Tagraxofusp) wird vergütet als Monotherapie für die Erstlinienbehandlung erwachsener Patienten mit blastischer plasmazytoider dendritischer Zellneoplasie (BPDCN).<br>\\nDie Verschreibung von ELZONRIS darf nur durch einen Facharzt der medizinischen Onkologie, Hämatologie oder Dermatologie mit Erfahrung in der Behandlung der BPDCN erfolgen.<br> \\n<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung ELZONRIS einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21579.01<br>\\n<br> \\n\",\"costApproval\":null,\"indication\":\"21579.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-06-01\",\"validTo\":\"2028-05-31\"}]",
  "galenic_form": "Inf Konz 1 mg/ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-01-01",
  "self_retention_pct": 10
}

See everything about tagraxofusp.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.